Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Respiratory infections in children up to two years of age on prophylaxis with palivizumab.

Monteiro AI, Bellei NC, Sousa AR, dos Santos AM, Weckx LY.

Rev Paul Pediatr. 2014 Jun;32(2):152-8. English, Portuguese.

2.

Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely.

Prais D, Kaplan E, Klinger G, Mussaffi H, Mei-Zahav M, Bar-Yishay E, Stafler P, Steuer G, Sirota L, Blau H.

Chest. 2016 Mar;149(3):801-8. doi: 10.1378/chest.15-0328. Epub 2016 Jan 5.

PMID:
26226546
3.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha IJ.

Cochrane Database Syst Rev. 2016 Jul 20;7:CD007743. doi: 10.1002/14651858.CD007743.pub6. Review.

PMID:
27439110
4.
5.

Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.

Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.

J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22.

6.

Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.

Han YM, Seo HJ, Choi SH, Jung YJ, Ahn SY, Yoo HS, Sung SI, Shim JW, Lee YK, Ko SY, Shin SM, Hwang JH, Lee JH, Choi BM, Kim ES, Jeon JH, Kim SS, Chang YS, Park WS.

J Korean Med Sci. 2015 Jul;30(7):924-31. doi: 10.3346/jkms.2015.30.7.924. Epub 2015 Jun 10. Erratum in: J Korean Med Sci. 2016 Feb;31(2):329.

7.

Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab.

Faldella G, Alessandroni R, Aquilano G, Vandini S, Lanari M, Silvestri M, Pistorio A, Rossi GA.

J Chemother. 2010 Feb;22(1):30-5.

PMID:
20227990
8.

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab.

Boivin G, Caouette G, Frenette L, Carbonneau J, Ouakki M, De Serres G.

J Clin Virol. 2008 May;42(1):52-7. doi: 10.1016/j.jcv.2007.11.012. Epub 2008 Feb 27.

PMID:
18164233
9.

Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.

Banerji A, Lanctôt KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, Roberts A.

Pediatr Infect Dis J. 2009 Aug;28(8):702-6. doi: 10.1097/INF.0b013e31819df78e.

PMID:
19461555
10.

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.

Pediatr Pulmonol. 2008 Feb;43(2):169-74.

PMID:
18085710
11.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha IJ.

Cochrane Database Syst Rev. 2014 May 22;(5):CD007743. doi: 10.1002/14651858.CD007743.pub5. Review. Update in: Cochrane Database Syst Rev. 2016;7:CD007743.

PMID:
24851825
12.

Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.

Ozyurt A, Narin N, Baykan A, Argun M, Pamukcu O, Zararsiz G, Sunkak S, Uzum K.

Pediatr Pulmonol. 2015 Oct;50(10):1025-32. doi: 10.1002/ppul.23102. Epub 2014 Aug 25.

PMID:
25156973
13.

Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.

Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC Sr.

Pediatr Crit Care Med. 2011 Sep;12(5):580-8. doi: 10.1097/PCC.0b013e3182070990. Review.

PMID:
21200358
14.

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.

Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.

Turk J Pediatr. 2012 Jul-Aug;54(4):344-51.

PMID:
23692714
15.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha IJ, McKoy NA.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007743. doi: 10.1002/14651858.CD007743.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;(6):CD007743.

PMID:
22336832
16.

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.

Pediatrics. 2004 Dec;114(6):1612-9.

PMID:
15574623
17.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha IJ, McKoy NA.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD007743. doi: 10.1002/14651858.CD007743.pub4. Review. Update in: Cochrane Database Syst Rev. 2014;(5):CD007743.

PMID:
23737087
18.

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.

Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators..

Pediatr Infect Dis J. 2002 Jun;21(6):512-8.

PMID:
12182374
19.

Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.

Groves HE, Jenkins L, Macfarlane M, Reid A, Lynn F, Shields MD.

Pediatr Pulmonol. 2016 Apr;51(4):379-85. doi: 10.1002/ppul.23376. Epub 2016 Jan 25.

PMID:
26808981
20.

Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.

Warren A, Langley JM, Thomas W, Scott J.

Can J Cardiol. 2007 May 1;23(6):463-6. Erratum in: Can J Cardiol. 2010 Jan;15(1):22.

Supplemental Content

Support Center